Literature DB >> 9774648

Viral oncoproteins discriminate between p53 and the p53 homolog p73.

M C Marin1, C A Jost, M S Irwin, J A DeCaprio, D Caput, W G Kaelin.   

Abstract

p73 is a recently identified member of the p53 family. Previously it was shown that p73 can, when overproduced in p53-defective tumor cells, activate p53-responsive promoters and induce apoptosis. In this report we describe the generation of anti-p73 monoclonal antibodies and confirm that two previously described p73 isoforms are produced in mammalian cells. Furthermore, we show that these two isoforms can bind to canonical p53 DNA-binding sites in electrophoretic mobility shift assays. Despite the high degree of similarity between p53 and p73, we found that adenovirus E1B 55K, simian virus 40 T, and human papillomavirus E6 do not physically interact with p73. The observation that viral oncoproteins discriminate between p53 and p73 suggests that the functions of these two proteins may differ under physiological conditions. Furthermore, they suggest that inactivation of p73 may not be required for transformation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774648      PMCID: PMC109218          DOI: 10.1128/MCB.18.11.6316

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  Abrogation of p53-mediated transactivation by SV40 large T antigen.

Authors:  K Segawa; A Minowa; K Sugasawa; T Takano; F Hanaoka
Journal:  Oncogene       Date:  1993-03       Impact factor: 9.867

2.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

Authors:  M Scheffner; B A Werness; J M Huibregtse; A J Levine; P M Howley
Journal:  Cell       Date:  1990-12-21       Impact factor: 41.582

3.  Wild-type p53 activates transcription in vitro.

Authors:  G Farmer; J Bargonetti; H Zhu; P Friedman; R Prywes; C Prives
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

5.  Identification of mutations in p53 that affect its binding to SV40 large T antigen by using the yeast two-hybrid system.

Authors:  B Li; S Fields
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

6.  Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.

Authors:  M Scheffner; T Takahashi; J M Huibregtse; J D Minna; P M Howley
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.

Authors:  J Bargonetti; I Reynisdóttir; P N Friedman; C Prives
Journal:  Genes Dev       Date:  1992-10       Impact factor: 11.361

8.  A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18.

Authors:  J M Huibregtse; M Scheffner; P M Howley
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

9.  The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.

Authors:  J A Mietz; T Unger; J M Huibregtse; P M Howley
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

10.  Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells.

Authors:  V Band; S Dalal; L Delmolino; E J Androphy
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  45 in total

1.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  The human p73 promoter: characterization and identification of functional E2F binding sites.

Authors:  Ratnam S Seelan; Meredith Irwin; Petra van der Stoop; Chiping Qian; William G Kaelin; Wanguo Liu
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

3.  Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.

Authors:  Takahito Nakagawa; Masato Takahashi; Toshinori Ozaki; Ken-ichi Watanabe Ki; Satoru Todo; Hiroyuki Mizuguchi; Takao Hayakawa; Akira Nakagawara
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Transcriptional activities of p73 splicing variants are regulated by inter-variant association.

Authors:  Y Ueda; M Hijikata; S Takagi; T Chiba; K Shimotohno
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

5.  DeltaNp73beta is active in transactivation and growth suppression.

Authors:  Gang Liu; Susan Nozell; Hui Xiao; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

6.  E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53.

Authors:  S Wienzek; J Roth; M Dobbelstein
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2.

Authors:  Marshall Urist; Tomoaki Tanaka; Masha V Poyurovsky; Carol Prives
Journal:  Genes Dev       Date:  2004-12-15       Impact factor: 11.361

Review 8.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

9.  p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.

Authors:  Michaela Beitzinger; Lars Hofmann; Claudia Oswald; Rasa Beinoraviciute-Kellner; Markus Sauer; Heidi Griesmann; Anne Catherine Bretz; Christof Burek; Andreas Rosenwald; Thorsten Stiewe
Journal:  EMBO J       Date:  2008-01-31       Impact factor: 11.598

Review 10.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.